VentiPET

VentiPET is developing the first PET-compatible gaseous radiopharmaceutical to transform how respiratory diseases are diagnosed and managed. Respiratory diseases affect more than 1 billion people worldwide, while current techniques for assessing pulmonary function still face major limitations in terms of accuracy, scalability, and clinical utility. For the first time, VentiPET enables fast visualization and quantification of regional pulmonary ventilation with the sensitivity and resolution of Positron Emission Tomography (PET). Our technology combines breakthrough imaging innovation with a scalable radiopharmaceutical distribution model already established, enabling seamless integration into existing clinical infrastructure. Initially focused on high-impact indications such as lung cancer surgical planning, VentiPET aims to improve clinical decision-making, personalize patient management, and unlock a new generation of functional respiratory imaging. Backed by granted international patents, clinical validation, and collaborations with leading clinical and industrial partners, VentiPET is positioned to become the future gold standard in pulmonary ventilation diagnostics.